For nearly two years, WuXi AppTec, the Chinese contract research giant with extensive ties with U.S. biotech and pharmaceutical companies, operated under cloud, as Congress threatened to restrict its ...

China's WuXi group is on roll. Three leading firms in the drug services family are all coasting to bigger half-year profits, raising investor hopes of a sustained sectoral upswing. The WuXi trio ...

WuXi Biologics' pre-filled syringes (PFS) commercial production line passed its first FDA inspection, paving the way for global delivery of high-quality PFS solutions to clients worldwide Reinforces ...

Shortly after WuXi AppTec provided an upbeat outlook for 2025, several other WuXi sibling companies are coming forward with their own 2024 success stories and ambitions for the year to come. First to ...

WuXi Biologic's facility in Worcester, seen here in December. Progress at the site has been slow, as the China-based firm has sold off some of its international assets. PHOTO ERIC CASEY CORRECTION: ...

WuXi AppTec Co. and WuXi Biologics Cayman Inc. said they see a brighter 2025 for the Chinese biotech and drug companies after the US Biosecure legislation that threatened to cut them out from their ...

China's WuXi AppTec has agreed to sell a business unit serving the cell and gene therapy (CGT) sector to private equity firm Altaris for an undisclosed sum. The contract development and manufacturing ...

With the specter of the BIOSECURE Act clouding its future, China’s WuXi AppTec sustained its fourth straight period with a year-over-year revenue decline as the contract research, development and ...

Shares of WuXi AppTec and WuXi Biologics surged in Hong Kong on Friday, following a report that the two firms are looking to divest some of their operations in the wake of new United States ...

Oct 3 (Reuters) - WuXi AppTec (603259.SS), opens new tab and WuXi Biologics (2269.HK), opens new tab are planning to sell some of their operations after the Chinese biotech companies were targeted by ...

(Reuters) -WuXi AppTec and WuXi Biologics are planning to sell some of their operations after the Chinese biotech companies were targeted by the U.S. on national security grounds, the Financial Times ...

Wuxi AppTec and Wuxi Biologics shares tumbled in Hong Kong after the US House of Representatives approved a bill that would restrict business with certain targeted Chinese biotech companies, setting ...